Valuation: Daebongls.Co.,Ltd.

Market Cap 85.14B 62.47M 55.49M 51.89M 47.29M 89.02M 6.01B 90.25M 628M 243M 3.06B 235M 229M 9.84B P/E 2024
20.1x
P/E 2025 13.5x
Enterprise Value 97.12B 71.25M 63.29M 59.19M 53.93M 102M 6.86B 103M 716M 277M 3.49B 268M 262M 11.22B EV / Sales 2024
1.35x
EV / Sales 2025 1.38x
Free-Float
47.83%
Yield 2024
0.37%
Yield 2025 -
08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-23 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-05 Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026 CI
25-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-05 Daebongls.Co.,Ltd. announced that it has received KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation ands another investor CI
24-09-03 Daebongls.Co.,Ltd. announced that it expects to receive KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation and another investor CI
24-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-16 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
1 day+0.39%
1 week+4.07%
Current month+0.39%
1 month-7.02%
3 months+6.52%
6 months-23.66%
Current year-34.08%
1 week 7,540
Extreme 7540
8,970
1 month 7,270
Extreme 7270
8,970
Current year 6,780
Extreme 6780
12,380
1 year 6,780
Extreme 6780
13,170
3 years 6,780
Extreme 6780
26,700
5 years 6,780
Extreme 6780
26,700
10 years 4,025
Extreme 4025
26,700
Manager TitleAgeSince
Chief Executive Officer 81 2013-03-26
Chief Executive Officer 55 2011-05-09
Comptroller/Controller/Auditor 68 2023-03-28
Director TitleAgeSince
Director/Board Member 55 2011-05-09
Director/Board Member 81 2013-03-26
Director/Board Member 58 2021-03-29
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%+4.07%-41.37%-19.58% 62.47M
-0.62%-2.71%+39.30%+114.07% 1,025B
-2.30%-4.44%+39.03%+66.07% 623B
-0.63%-1.96%+6.36%+74.38% 459B
-1.03%-2.82%+59.56%+39.69% 355B
-0.33%-3.58%+22.19%+40.05% 336B
-0.28%-1.65%+13.27%+26.19% 270B
-0.31%-4.49%-3.74%+9.48% 247B
-3.38%+0.30%+36.44%+51.54% 220B
-1.04%-1.46%+32.70%+96.82% 183B
Average -0.69%-1.30%+20.37%+49.87% 371.83B
Weighted average by Cap. -0.65%-2.11%+30.33%+69.46%

Financials

2024 2025
Net sales 93.95B 68.93M 61.23M 57.26M 52.18M 98.23M 6.64B 99.58M 693M 268M 3.38B 259M 253M 10.86B 102B 74.88M 66.51M 62.2M 56.68M 107M 7.21B 108M 752M 291M 3.67B 281M 275M 11.79B
Net income 7.34B 5.38M 4.78M 4.47M 4.08M 7.67M 518M 7.78M 54.11M 20.95M 264M 20.22M 19.78M 848M 10.06B 7.38M 6.55M 6.13M 5.59M 10.52M 711M 10.66M 74.16M 28.71M 362M 27.71M 27.11M 1.16B
Net Debt -22.03B -16.17M -14.36M -13.43M -12.24M -23.04M -1.56B -23.35M -162M -62.89M -793M -60.7M -59.38M -2.55B 11.97B 8.78M 7.8M 7.3M 6.65M 12.52M 846M 12.69M 88.27M 34.17M 431M 32.98M 32.26M 1.38B
Logo Daebongls.Co.,Ltd.
DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.
Employees
131
Date Price Change Volume
26-10-01 ₩7,680.00 +0.39% 21,701
26-09-30 ₩7,650.00 -1.29% 19,472
26-09-29 ₩7,750.00 -2.02% 47,462
26-09-28 ₩7,910.00 +7.18% 292,184
26-09-23 ₩7,380.00 +0.14% 12,349
  1. Stock Market
  2. Stocks
  3. A078140 Stock